MX388732B - Formulaciones de antibioticos glicopeptidicos estabilizados - Google Patents

Formulaciones de antibioticos glicopeptidicos estabilizados

Info

Publication number
MX388732B
MX388732B MX2018013584A MX2018013584A MX388732B MX 388732 B MX388732 B MX 388732B MX 2018013584 A MX2018013584 A MX 2018013584A MX 2018013584 A MX2018013584 A MX 2018013584A MX 388732 B MX388732 B MX 388732B
Authority
MX
Mexico
Prior art keywords
glycopeptide antibiotic
antibiotic formulations
stabilized glycopeptide
stabilized
vancomycin
Prior art date
Application number
MX2018013584A
Other languages
English (en)
Other versions
MX2018013584A (es
Inventor
Ivona Jasprica
Jerome Le-Cunff
Sabina Keser
Original Assignee
Xellia Pharmaceuticals Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xellia Pharmaceuticals Aps filed Critical Xellia Pharmaceuticals Aps
Publication of MX2018013584A publication Critical patent/MX2018013584A/es
Publication of MX388732B publication Critical patent/MX388732B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica líquida que comprende vancomicina y sulfobutiléter-betaciclodextrina, donde la concentración de vancomicina en la formulación es de 0.5% a 10 % p/V, en donde la composición farmacéutica es estable durante al menos cuatro semanas a 25°C en un recipiente cerrado.
MX2018013584A 2016-05-09 2017-05-04 Formulaciones de antibioticos glicopeptidicos estabilizados MX388732B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662333357P 2016-05-09 2016-05-09
PCT/EP2017/060653 WO2017194385A1 (en) 2016-05-09 2017-05-04 Stabilized glycopeptide antibiotic formulations

Publications (2)

Publication Number Publication Date
MX2018013584A MX2018013584A (es) 2019-04-01
MX388732B true MX388732B (es) 2025-03-20

Family

ID=58745200

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013584A MX388732B (es) 2016-05-09 2017-05-04 Formulaciones de antibioticos glicopeptidicos estabilizados

Country Status (19)

Country Link
US (1) US10729708B2 (es)
EP (1) EP3454883A1 (es)
JP (1) JP6946343B2 (es)
KR (1) KR20190005940A (es)
CN (1) CN109069580A (es)
AR (1) AR109454A1 (es)
AU (1) AU2017262943B2 (es)
BR (1) BR112018072948A2 (es)
CL (1) CL2018003147A1 (es)
CO (1) CO2018011701A2 (es)
EA (1) EA201892413A1 (es)
IL (1) IL262796A (es)
JO (2) JOP20170111B1 (es)
MX (1) MX388732B (es)
SA (1) SA518400392B1 (es)
SG (1) SG11201809908TA (es)
TW (2) TWI772296B (es)
UY (1) UY37233A (es)
WO (1) WO2017194385A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE053347T2 (hu) 2014-11-06 2021-06-28 Xellia Pharmaceuticals Aps Glikopeptid-készítmények
US20210346288A1 (en) * 2020-05-11 2021-11-11 Cai Gu Huang Pharmaceutical formulation containing active metabolites of remdesivir for inhalation
WO2022031830A1 (en) * 2020-08-04 2022-02-10 Harrow Ip Llc Antibacterial compositions and methods for fabricating thereof
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
CN115804832A (zh) * 2021-09-14 2023-03-17 海南普利制药股份有限公司 一种万古霉素水溶液组合物
WO2023171588A1 (ja) * 2022-03-08 2023-09-14 国立大学法人大阪大学 抗菌薬を含有するｐｌｇａ製剤
US20250295727A1 (en) * 2022-04-26 2025-09-25 Hikma Pharmaceuticals Usa Inc. Stable, ready-to-administer aqueous formulations of dalbavancin
GB202207345D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
GB202207344D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
CN117618338A (zh) * 2022-08-16 2024-03-01 海南普利制药股份有限公司 一种稳定的奥利万星药物水溶液及其制备方法
EP4601615A1 (en) 2022-10-12 2025-08-20 Hikma Pharmaceuticals USA Inc. Liquid dalbavancin composition
AU2023359653A1 (en) * 2022-10-12 2025-05-29 Hikma Pharmaceuticals Usa Inc. Liquid dalbavancin composition
EP4431083A1 (en) * 2023-03-16 2024-09-18 Adalvo Limited Formulation of dalbavancin
WO2025158262A1 (en) * 2024-01-23 2025-07-31 Lupin Limited Stable pharmaceutical compositions of dalbavancin as ready-to-dilute formulation

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1278549A (en) * 1916-12-16 1918-09-10 J E Simmons Nut and bolt lock.
US4670258A (en) 1984-02-10 1987-06-02 Vanderbilt University Storable prepackaged aqueous solutions of vancomycin
US4885275A (en) 1987-10-15 1989-12-05 Eli Lilly And Company Vancomycin-HCL solutions and the lyophilization thereof
WO1997019690A1 (en) * 1995-12-01 1997-06-05 Eli Lilly And Company Stable vancomycin hydrochloride solutions
JPH1180021A (ja) 1997-09-02 1999-03-23 Kayaku:Kk バンコマイシン注射剤
US6770621B2 (en) 2000-05-02 2004-08-03 Theravance, Inc. Polyacid glycopeptide derivatives
JP4870314B2 (ja) * 2000-05-02 2012-02-08 セラヴァンス， インコーポレーテッド シクロデキストリンを含むグリコペプチド抗生物質組成物
KR100856479B1 (ko) * 2000-05-02 2008-09-04 세라밴스 인코포레이티드 환원성 알킬화 방법
BR0112393A (pt) * 2000-06-21 2003-07-08 Internat Health Man Associates Composições e processos para aperfeiçoamento de absorção oral de agentes antimicrobiais
UA75083C2 (uk) * 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
WO2005042584A2 (en) * 2003-10-31 2005-05-12 The University Of Kansas Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
EP1848413B1 (en) 2005-02-14 2014-04-09 Venus Remedies Limited Parenteral combination therapy for infective conditions with drug resistant bacterium
CN1857716A (zh) * 2006-03-14 2006-11-08 浙江大学 注射用盐酸万古霉素及其制备方法
JP2008201778A (ja) 2007-01-25 2008-09-04 Mochida Pharmaceut Co Ltd バンコマイシン液状製剤
EP2195004B1 (en) 2007-09-12 2015-04-01 The Medicines Company Method of inhibiting clostridium difficile by administration of oritavancin
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
CN102755629A (zh) * 2012-08-02 2012-10-31 上海瑞创医药科技有限公司 与万古霉素形成抗菌增效包合物的组分和制备方法及其应用
RU2018135921A (ru) 2012-11-29 2019-02-05 Инсмед Инкорпорейтед Стабилизированные составы ванкомицина
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
WO2014194296A1 (en) 2013-05-30 2014-12-04 Scidose, Llc Formulations of vancomycin
HUE053347T2 (hu) * 2014-11-06 2021-06-28 Xellia Pharmaceuticals Aps Glikopeptid-készítmények
EA036750B1 (ru) 2016-01-08 2020-12-16 Гуфик Байосайенсиз Лимитед Лиофилизированная парентеральная композиция тигециклина и способ ее приготовления
RU2018129076A (ru) * 2016-02-18 2020-03-18 Мелинта Терапьютикс, Инк. Составы оритаванцина

Also Published As

Publication number Publication date
JOP20220039A1 (ar) 2023-01-30
IL262796A (en) 2018-12-31
KR20190005940A (ko) 2019-01-16
SG11201809908TA (en) 2018-12-28
UY37233A (es) 2018-01-02
JOP20170111B1 (ar) 2022-03-15
JP2019518733A (ja) 2019-07-04
US20190175632A1 (en) 2019-06-13
CL2018003147A1 (es) 2018-12-28
TWI769694B (zh) 2022-07-01
WO2017194385A1 (en) 2017-11-16
SA518400392B1 (ar) 2022-05-09
TWI772296B (zh) 2022-08-01
EA201892413A1 (ru) 2019-05-31
TW201740955A (zh) 2017-12-01
JP6946343B2 (ja) 2021-10-06
US10729708B2 (en) 2020-08-04
CO2018011701A2 (es) 2019-02-08
MX2018013584A (es) 2019-04-01
EP3454883A1 (en) 2019-03-20
BR112018072948A2 (pt) 2019-02-19
TW202133875A (zh) 2021-09-16
AU2017262943B2 (en) 2020-05-14
CA3021935A1 (en) 2017-11-16
AU2017262943A1 (en) 2018-11-22
AR109454A1 (es) 2018-12-12
CN109069580A (zh) 2018-12-21

Similar Documents

Publication Publication Date Title
MX388732B (es) Formulaciones de antibioticos glicopeptidicos estabilizados
CL2017001115A1 (es) Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.
NZ743964A (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
MX2021006035A (es) Formulaciones cannabinoides estables.
CL2018003178A1 (es) Composición farmacéutica
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
DOP2017000137A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo.
BR112017007393A2 (pt) composições de anticorpo anti-il-7r
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
CO6680698A2 (es) Formulación de premezcla de dexmedetomidina
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
AR089931A1 (es) Composiciones farmaceuticas que contienen dimetilfumarato
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
BR112015032541A2 (pt) conservação de composições para cuidados pessoais
BR112017000313A2 (pt) sistema para o fornecimento de uma composição para tratamento bucal, composição para tratamento bucal, método para administrar uma composição para tratamento bucal
EP3725321A4 (en) COMPOSITION WITH A BACTERIUM OF THE GENUS BIFIDOBACTERIUM AS THE ACTIVE SUBSTANCE
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
GT201700124A (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2018001984A1 (es) Formulación líquida estable de gonadotropina.
UA110979C2 (uk) Рідка фармацевтична композиція, яка включає нітизинон
NZ702342A (en) Pharmaceutical formulation
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
BR112017026904A2 (pt) formulações farmacêuticas injetáveis de lefamulina
MX2023008569A (es) Formulaciones farmaceuticas mejoradas.
MX2021004418A (es) Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento.